Table 1.

Comparisons of response rates (RR) progression free survival (PFS) in elotuzumab clinical trials.

Phase	Regimen*	N*	Overall RR	Median PFS	References
I	Elo	35	0%	N/A	(40)
I	Elo/Bor	27	48%	9.46 months	(41)
II	Elo/Bor/Dex vs. Bor/Dex	150	66 vs. 63%	9.7 vs. 6.9 months	(47)
I	Elo/Len/Dex	28	82%	N/A	(48)
Ib/II	Elo/Len/Dex	73	84%	28.6 months	(49)
III	Elo/Len/Dex vs. Len/Dex	646	79 vs. 66%	19.4 vs. 14.9 months	(50)
II	Elo/Td/Dex	40	38%	3.9 months	(51)
II	Elo/Pom/Dex vs. Pom/Dex	117	53 vs. 26%	10.3 vs. 4.7 months	(52)

^*Elo, elotuzumab; Bor, bortezomib; Dex, dexamethasone; Len, lenalidomide; Td, thalidomide; Pom, pomalidomide; n, number of evaluable patients.